Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
The Scientific World Journal, 2015 SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced.
L. Zanoli +6 more
doaj +1 more source
The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) [PDF]
Hospital PharmacologyIntroduction: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors play a crucial role in type 2 diabetes treatment, exerting effects on proximal tubules to reduce glucose reab-sorption and enhance urinary excretion, offering cardiovascular and ...
Denda Nikola I. +4 more
doaj +1 more source
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Cardiovascular Diabetology, 2022 Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by chronic hyperglycemia causing from insufficient insulin signaling because of insulin resistance or defective insulin secretion, and may induce severe complications ...
Bo Xu, Shaoqian Li, Bo Kang, Jiecan Zhou
doaj +1 more source
Endocrine Journal, 2023 Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of antidiabetic drugs. Guidelines for the proper use of SGLT2 inhibitors recommend caution regarding urinary tract infections (UTIs).
Go Anan +5 more
doaj +1 more source
Lack of Evidence for a Harmful Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials [PDF]
, 2016 Aim To evaluate the comparative effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on risk of bone fracture in patients with type 2 diabetes mellitus (T2DM).
Hsu, Y. H. +6 more
core +2 more sources
Microvascular Disease with Heart Failure with Reduced and Preserved Ejection Fraction in Patients with Type 2 Diabetes [PDF]
, 2020 Aims: Identification of patients with type 2 diabetes (T2D) at increased risk of incident heart failure (HF) beyond traditional risk factors such as prior myocardial infarction (MI) might allow selection of patients who would benefit from preventative ...
Doney, Alexander +5 more
core +2 more sources
Inhibitor binding mode and allosteric regulation of Na+-glucose symporters. [PDF]
, 2018 Sodium-dependent glucose transporters (SGLTs) exploit sodium gradients to transport sugars across the plasma membrane. Due to their role in renal sugar reabsorption, SGLTs are targets for the treatment of type 2 diabetes.
Althoff, Thorsten +9 more
core +2 more sources
Journal of Primary Care & Community HealthIntroduction: There remains an unmet need to reduce kidney and cardiovascular risk in patients with chronic kidney disease (CKD). This report is therefore intended to provide real-world clinical guidance to primary care providers on sodium-glucose co ...
Anjay Rastogi +7 more
doaj +1 more source
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Cardiovascular Diabetology, 2020 Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF).
Atsushi Tanaka, Koichi Node
doaj +1 more source
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? [PDF]
, 2016 While the modest reduction in the primary composite outcome of myocardial infarction, stroke or cardiovascular death in the EMPA-REG Outcomes trial was welcome, the 30–40% reductions in heart failure hospitalisation (HFH) and cardiovascular and all-cause
David Preiss +4 more
core +2 more sources